These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31881283)

  • 1. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
    Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
    Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
    Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
    Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
    Sasaki K; Lu G; Saliba RM; Bashir Q; Hosing C; Popat U; Shah N; Parmar S; Dinh Y; Ahmed S; Shpall EJ; Kebriaei P; Shah JJ; Orlowski RZ; Champlin R; Qazilbash MH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1227-32. PubMed ID: 23733001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.
    Pasvolsky O; Milton DR; Rauf M; Tanner MR; Bashir Q; Srour S; Tang G; Saini N; Ramdial J; Masood A; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2022 Nov; 28(11):752.e1-752.e6. PubMed ID: 35940528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
    Shah GL; Landau H; Londono D; Devlin SM; Kosuri S; Lesokhin AM; Lendvai N; Hassoun H; Chung DJ; Koehne G; Jhanwar SC; Landgren O; Levine R; Giralt SA
    Leuk Lymphoma; 2017 Aug; 58(8):1823-1831. PubMed ID: 28078910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
    Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
    Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
    Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
    Hu B; Thall P; Milton DR; Sasaki K; Bashir Q; Shah N; Patel K; Popat U; Hosing C; Nieto Y; Lin P; Delgado R; Jorgensen J; Manasanch E; Weber D; Thomas S; Orlowski RZ; Champlin R; Qazilbash MH
    Leuk Lymphoma; 2019 Feb; 60(2):442-452. PubMed ID: 30032678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
    Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
    Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
    Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
    Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.